(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 65.11% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Sangamo Therapeutics's revenue in 2024 is $18,756,000.On average, 4 Wall Street analysts forecast SGMO's revenue for 2024 to be $9,075,868,194, with the lowest SGMO revenue forecast at $6,733,701,966, and the highest SGMO revenue forecast at $10,479,258,838. On average, 4 Wall Street analysts forecast SGMO's revenue for 2025 to be $19,494,534,090, with the lowest SGMO revenue forecast at $6,864,433,314, and the highest SGMO revenue forecast at $47,519,807,404.
In 2026, SGMO is forecast to generate $15,038,670,228 in revenue, with the lowest revenue forecast at $10,850,701,874 and the highest revenue forecast at $20,232,232,410.